The human immunodeficiency virus (HIV) is a viral infection that destroys the human immune system resulting in acquired immunodeficiency syndrome (AIDS). The Zambia HIV prevalence rate (11.3%) remains among the highest in the sub-Saharan Africa. In the treatment of HIV-naive patients, a problem that relates to the transmitted drug resistance mutation strains (TDRMs) occurs in the administration of antiretroviral (ARV) drugs. To address this problem, we propose the use of transition probabilities when prescribing a switch from the first-line to the second-line or to the third-line regimen on the ARV drugs combination. We formulate a statistical technique to determine an optimal ARV drugs combination. To compute a transition probability matrix chart on ARV drugs combinations of the first-line and second-line regimens, we apply a beta-binomial hierarchical model on HIV data. The transition probability matrices corresponding to the ARV drugs combinations TDF+ETC+NVP, TDF+FTC+EFV, AZT+3TC+NVP, AZT+3TC+EFV, D4T+3TC+NVP, and D4T+3TC+EFV provide an upper triangular matrix of probabilities. We observe a higher probability of remaining in the same regimen state than moving to another state. A transition probability chart provides information on the most effective combination to prescribe to a patient in the presence of transmitted drug resistance mutation (TDRM) test results. The transmission probabilities play a major role in aiding the physicians make an informed decision to prescribe an optimal ARV drugs combination. We suggest a TDRM test to be carried out to all newly diagnosed HIV individuals before prescribing any of the ARV drugs combination.
Get full access to this article
View all access options for this article.
References
1.
SpauldingA, RutherfordGW, SiegfriedN: Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals. Cochrane Database Syst Rev 201010:CD008740.
2.
BoydMA, HillAM: Clinical management of treatment-experienced, HIV/AIDS patients in the combination antiretroviral therapy era. Pharmacoeconomics, 2010; 28(S1):17–34.
3.
RodesB, GarcíaF, GutierrezC, et al.: Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. J Med Virol, 2005; 77:23–28.
4.
VrayM, MeynardJ-L, DalbanC, et al.: Predictors of the virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther (Lond), 2003; 8:427–434.
5.
BulteelN, Bansi-MatharuL, ChurchillD, et al.: The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort. J Infect, 2014; 68:77–84.
6.
MarcelinAG, CharpentierC, WirdenM, et al.: Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens. J Antimicrob Chemother, 2012; 67:1475–1478.
7.
OmejeI, OkwunduCI: Effectiveness and safety of first-line fixed-dose TNF + EMC + EFZ for patients with HIV. In: The Cochrane Collaboration, ed. Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd., Chichester, UK, 2008.
8.
OnoyaD, HirasenK, van den BergL, MiotJ, LongLC, FoxMP: Adverse drug reactions among patients initiating second-line antiretroviral therapy in South Africa. Drug Safety, 2018; 41:1343–1353.
9.
SturtAS, DokuboEK, SintTT: Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women. Cochrane Database Syst Rev, 2010; 3:CD008440.
10.
BonuraF, TramutoF, VitaleF, PernaAM, VivianoE, RomanoN: Transmission of drug-resistant HIV type 1 strains in HAART-naive patients: A 5-year retrospective study in Sicily, Italy. AIDS Res Hum Retroviruses, 2010; 26:961–965.
11.
KühnertD, KouyosR, ShirreffG, et al.: Quantifying the fitness cost of HIV-1 drug resistance mutations through phylodynamics. PLoS Pathog, 2018; 14:e1006895.
12.
LuX, ZhaoH, ZhangY, et al.: HIV-1 drug-resistant mutations and related risk factors among HIV-1-positive individuals experiencing treatment failure in Hebei Province, China. AIDS Res Ther, 2017; 14:4.
13.
SallamM, ŞahinGÖ, IndriðasonH, et al.: Decreasing prevalence of transmitted drug resistance among ART-naive HIV-1-infected patients in Iceland, 1996–2012. Infect Ecol Epidemiol, 2017; 7:1328964.
14.
WertheimJO, OsterAM, JohnsonJA, et al.: Transmission fitness of drug-resistant HIV revealed in a surveillance system transmission network. Virus Evol, 2017; 3:vex008.
15.
SungkanuparphS, ManosuthiW, KiertiburanakulS, PiyavongB, ChumpathatN, ChantratitaW: Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails. Clin Infect Dis, 2007; 44:447–452.
16.
JiamsakulA, SirivichayakulS, DitangcoR, et al.: Transmitted drug resistance in recently infected HIV-positive Individuals from four urban locations across Asia (2007–2010)—TASER-S. AIDS Res Ther, 2015; 12:3.
17.
PhanuphakP, SirivichayakulS, JiamsakulA, et al.: Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1—Infected patients in South East Asia. J Acquir Immune Defic Syndromes, 2014; 66:74–79.
18.
TripathiRC, GuptaRC, GurlandJ: Estimation of parameters in the beta binomial model. Ann Inst Statistic Math, 1994; 46:317–331.
19.
TangMW, RheeS-Y, BertagnolioS, et al.: Nucleoside reverse transcriptase inhibitor resistance mutations associated with first-line stavudine-containing antiretroviral therapy: Programmatic implications for countries phasing out stavudine. J Infect Dis, 2013; 207(Suppl 2):S70–S77.
20.
TakouD, FokamJ, TetoG, et al.: HIV-1 drug resistance testing is essential for heavily-treated patients switching from first- to second-line regimens in resource-limited settings: Evidence from routine clinical practice in Cameroon. BMC Infect Dis, 2019; 19:246.
21.
WHO | World Health Statistics: WHO. Available at https://www.who.int/whosis/whostat/2009/en (2009), accessed January30, 2020.
22.
HardonA, DaveyS, GerritsT, World HealthOrganization, Universiteit vanAmsterdam, Koninklijk Instituut voor deTropen, eds: From Access to Adherence: The Challenges of Antiretroviral Treatment: Studies from Botswana, Tanzania and Uganda 2006. World Health Organization, 2006.
23.
KotakiT, KhairunisaSQ, WitaningrumAM, et al.: HIV-1 transmitted drug resistance mutations among antiretroviral therapy-Naïve individuals in Surabaya, Indonesia. AIDS Res Ther, 2015; 12:5.
24.
MelikianGL, RheeS-Y, VargheseV, et al.: Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: Implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing. J Antimicrob Chemother, 2014; 69:12–20.
25.
SeuL, MulengaLB, SiwingwaM, et al.: Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia: Sequence Analysis of HIV DRMs in Lusaka, Zambia. J Med Virol, 2015; 87:1149–1157.
26.
LunnDJ, ThomasA, BestN, SpiegelhalterD: WinBUGS—A Bayesian modelling framework: Concepts, structure, and extensibility. Stat Comput, 2000; 10:325–337.
27.
BrooksSP, GelmanA: General methods for monitoring convergence of iterative simulations. J Comput Graph Stat, 1998; 7:434–455.
28.
WandelerG, KeiserO, MulengaL, et al.: Tenofovir in second-line ART in Zambia and South Africa: Collaborative analysis of cohort studies. J Acquir Immune Defic Syndr, 2012; 61:41–48.
29.
ChiBH, MwangoA, GigantiM, et al.: Early clinical and programmatic outcomes with tenofovir-based antiretroviral therapy in Zambia. J Acquir Immune Defic Syndr, 2010; 54:63–70.
30.
NjugunaC, OrrellC, KaplanR, BekkerL-G, WoodR, LawnSD: Rates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovir. PLoS One, 2013; 8:e63596.
31.
GelmanA: Bayes, Jeffreys, Prior Distributions and the Philosophy of Statistics. Stat Sci, 2009; 24:176–178.
32.
JeffreysH: An invariant form for the prior probability in estimation problems. Proc R Soc Lond A, 1946; 186:453–461.
33.
AliyuA, El-KamaryS, BrownJ, et al.: Performance and trend for quality of service in a large HIV/AIDS treatment program in Nigeria. AIDS Res Ther, 2019; 16:29.
